Multinational, multicenter, retrospective cohort study assessing treatment patterns and outcomes in solid organ transplant recipients considered refractory, resistant, or intolerant to anti-CMV therapies

Introduction Real-world evidence on cytomegalovirus (CMV) infection after solid organ transplant (SOT) is limited, particularly with refractory, resistance, and/or intolerance to anti-CMV agents (RRI). Methods This retrospective chart review study across 15 transplant centers in Canada, Israel, and Europe included adult SOT recipients with RRI CMV infection. Results Overall, patients ( N = 109) experienced 169 CMV episodes, with a median (Q1–Q3) time from SOT to the first CMV episode of 119 days (46–231) and from SOT to RRI diagnosis of 187 (100–296) days. CMV clearance during the first RRI CMV episode was achieved by 83 patients (76.1%) (median time to clearance: 48 days from the start of the index episode, 32 days from RRI diagnosis). Recurrent CMV episodes occurred in 30.3% of patients ( n = 33; median time to recurrence from the end of the index episode, 42 days). In total, 70 patients (64.2%) experienced myelosuppression and 16 (14.7%) experienced nephrotoxicity. Overall, 26 patients (23.9%) experienced organ rejection and 6.4% ( n = 7) graft loss after RRI diagnosis. Overall, 28 patients (25.7%) died following SOT. Conclusion Post-SOT RRI CMV infection may lead to high treatment burden and negatively affect outcomes. There is a need for anti-CMV therapies that can achieve CMV clearance without treatment-limiting toxicities.

Authors

Institutions

Publication Details

Journal
Frontiers in Transplantation
Published
2026-11-19
DOI
https://doi.org/10.3389/frtra.2026.1867958
Primary Topic
Cytomegalovirus and herpesvirus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Multinational, multicenter, retrospective cohort study assessing treatment patterns and outcomes in solid organ transplant recipients considered refractory, resistant, or intolerant to anti-CMV therapies

Paolo Grossi, Luca Toti, François Gavini, Merel E. Hellemons et al.
Frontiers in Transplantation
Cytomegalovirus and herpesvirus research
article

Multinational, multicenter, retrospective cohort study assessing treatment patterns and outcomes in solid organ transplant recipients considered refractory, resistant, or intolerant to anti-CMV therapies

Paolo Grossi, Luca Toti, François Gavini, Merel E. Hellemons, Ilaria Albieri, Tien Bo, Judith Kahn, Irmgard Andresen, Sara Belga
article en

Abstract

Introduction Real-world evidence on cytomegalovirus (CMV) infection after solid organ transplant (SOT) is limited, particularly with refractory, resistance, and/or intolerance to anti-CMV agents (RRI). Methods This retrospective chart review study across 15 transplant centers in Canada, Israel, and Europe included adult SOT recipients with RRI CMV infection. Results Overall, patients ( N = 109) experienced 169 CMV episodes, with a median (Q1–Q3) time from SOT to the first CMV episode of 119 days (46–231) and from SOT to RRI diagnosis of 187 (100–296) days. CMV clearance during the first RRI CMV episode was achieved by 83 patients (76.1%) (median time to clearance: 48 days from the start of the index episode, 32 days from RRI diagnosis). Recurrent CMV episodes occurred in 30.3% of patients ( n = 33; median time to recurrence from the end of the index episode, 42 days). In total, 70 patients (64.2%) experienced myelosuppression and 16 (14.7%) experienced nephrotoxicity. Overall, 26 patients (23.9%) experienced organ rejection and 6.4% ( n = 7) graft loss after RRI diagnosis. Overall, 28 patients (25.7%) died following SOT. Conclusion Post-SOT RRI CMV infection may lead to high treatment burden and negatively affect outcomes. There is a need for anti-CMV therapies that can achieve CMV clearance without treatment-limiting toxicities.

Frontiers in TransplantationVol. 5
University of Insubria (IT), University of Rome Tor Vergata (IT), University of British Columbia (CA), Medical University of Graz (AT), Erasmus MC (NL), Takeda (Switzerland) (CH), Takeda (United States) (US), Erasmus MC Transplant Institute (NL), Aziende Socio Sanitarie Territoriale dei Sette Laghi (IT)
Cytomegalovirus and herpesvirus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon